ContractRadiology Clinical Trial Agreement • August 11th, 2021
RADIOLOGY CLINICAL TRIAL AGREEMENT Concluded in accordance with § 1746 (2) of the Act. No. 89/2012 Coll., Civil Code, as amended. SMLOUVA O SLUŽBÁCH RADIOLOGIE V KLINICKÉM HODNOCENÍ Uzavřená v souladu s ustanovením § 1746 odst.2 zák. č. 89/2012 Sb., občanský zákoník, ve znění pozdějších předpisů. For Trial MOR208C310. “A phase 3, multicenter, randomized, double- blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R- CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL)” (hereinafter referred to as “Trial”) This Radiology Clinical Trial Agreement (the “Agreement”) is entered into with effect as of the date of publishing in the Contract Register (the “Effective Date”), is entered into by and between: MorphoSys AG, a German pharmaceutical company with a principal place of business at Semmelweisstr. 7, 82152 Planegg, Germany,VAT: DE1550698
